AMACR has first been found upregulated in prostate cancer by Xu et al (2000) using suppressive subtractive hybridisation, and AMACR antibodies have become available quickly thereafter (Jiang et al, 2001; Rubin et al, 2002). This evidence concerns the gene AMACR and prostate carcinoma.